Efficacy and Safety of the Fixed Dose Combination of Glimepiride+Metformin in Type 2 Diabetic Patients Inadequately Controlled

• Status: Completed
• Trial end date: 2014-04-01

Summary

Primary Objective:

-To demonstrate the efficacy of a fixed combination of glimepiride + metformin in terms of HbA1c reduction, during 24-week treatment period in patients with inadequately controlled type 2 diabetes mellitus.

Secondary Objective:

To assess the effects of the fixed combination of glimepiride and metformin at week 24 on:

• Percentage of patients reaching HbA1c <7%

• Percentage of patients reaching HbA1c <6.5%.

• Fasting Plasma Glucose (FPG)

• Safety and tolerability

• Phase: Phase 3

Details

• Lead Sponsor: Sanofi
• Treatments: Glimepiride; Metformin